PER® Miami Breast Cancer Conference | Conference

TV Anchor Amy Robach Delivers Riveting Keynote on Breast Cancer Survival

March 12th 2016

Breast cancer survivor and Good Morning America news anchor Amy Robach delivered a compelling keynote address at the 33rd Annual Miami Breast Cancer ConferenceÂ®.

Alpelisib Combo Promising in PIK3CA-Altered, Heavily Pretreated Breast Cancer

March 12th 2016

The combination of the alpha-specific PI3K inhibitor alpelisib (BYL719) and fulvestrant (Faslodex) demonstrated promising early efficacy and mild toxicity in heavily pretreated postmenopausal women with ER-positive metastatic breast cancer.

Nab-Paclitaxel Outduels Paclitaxel in HR+/HER2- and Triple-Negative MBC

March 12th 2016

Among patients with HR+/HER2- or triple-negative metastatic breast cancer, nab-paclitaxel (Abraxane) improved time to treatment discontinuation, time to next treatment, and had a favorable safety profile compared with paclitaxel.

Dr. Mittendorf on Nelipepimut-S Plus GM-CSF in Breast Cancer

March 11th 2016

Elizabeth A. Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses a clinical trial examining nelipepimut-S plus GM-CSF vaccine therapy as a treatment for patients with breast cancer.

Beyond OS: Common Sense Endpoints for Cancer Drugs

March 11th 2016

The rapid advance of oncology drug development requires evolving beyond using overall survival in randomized trials as the only acceptable endpoint.

Lack of Understanding of Margin Width Remains a Hindrance in DCIS

March 11th 2016

There is no clearly acceptable answer to the question of what is the appropriate margin for ductal carcinoma in situ.

More Data Needed to Confirm Early Results on Carboplatin in TNBC

March 11th 2016

Carboplatin shows promise in treating metastatic BRCA-mutated triple negative breast cancer.

Dr. Symmans on Moon Shots Program for Patients With TNBC

March 11th 2016

William F. Symmans, MB, ChB, Division of Pathology/Lab Medicine, Department of Pathology, The University of Texas MD Anderson Cancer Center, discusses the institution's Moon Shots program for patients with triple-negative breast cancer.

Dr. Blackwell on Late Recurrences in Patients With Breast Cancer

March 10th 2016

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses using the word "cure" in patients with breast cancer who have not had recurrences of disease.

Evolving Role of Lymph Node Biopsies After Neoadjuvant Therapy for Breast Cancer

March 23rd 2015

OncLive spoke with Kelly K. Hunt, MD, about how breast cancer interventions have progressed in the adjuvant and neoadjuvant setting and about the role of sentinel lymph node dissection in the neoadjuvant setting.

Dixon Questions Value of Chemoprevention With Tamoxifen

March 3rd 2015

The reduction of breast cancer risk with 5 years of tamoxifen does not outweigh the lack of a mortality benefit, according to J. Michael Dixon, MD, OBE, who shared his view in a session at the 32nd Annual Miami Breast Cancer Conference.

The Doctor Will Tweet With You Now: Social Media for Oncologists

March 3rd 2015

Deanna J. Attai, MD, FACS, who interacts with her thousands of followers on Twitter, Facebook, YouTube, her blog, and other social media platforms, recently educated other physicians on what their role can be on social media.

Top MBCC Abstracts Focus on Tumor Profiling and Radiotherapy Paradigms

March 2nd 2015

A detailed tumor profile of molecular and protein alterations in a rare breast cancer subtype and a retrospective analysis about the impact of radiation after breast conserving surgery took home top honors at the Miami Breast Cancer Conference this year.

US Lags in Adopting Hypofractionated Radiation Standard

March 2nd 2015

Compelling clinical trial evidence supports the use of hypofractionated radiation as the standard of care for postmenopausal women with luminal A tumors and node-negative disease.

Dr. Pegram on Challenges in Neoadjuvant Treatment for HER2-Positive Breast Cancer

February 28th 2015

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, goes over some of the challenges surrounding neoadjuvant treatment for HER2-positive breast cancer patients.

Dr. Muss on Optimizing Adjuvant Treatment for Older Breast Cancer Patients

February 28th 2015

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses optimizing adjuvant treatment in older patients with breast cancer.

Joan Lunden Paints a Picture of Breast Cancer From the Patient's Perspective

February 28th 2015

Joan Lunden presented the keynote address at the Miami Breast Cancer Conference where she spoke powerfully and from the heart in a talk perfectly aligned with the meeting's focus on the patient perspective.

Heterogeneity Complicates Treatment Decisions in Breast Cancer

February 28th 2015

Heterogeneity, which can result in treatment resistance, is commonly underestimated and misunderstood, representing an important area of future research.

Hudis Highlights Interplay Between Inflammation, Obesity, and Breast Cancer

February 28th 2015

In a discussion at the Miami Breast Cancer Conference, Clifford A. Hudis, MD, suggested that an increased risk for developing breast cancer might be a consequence of inflammation that often accompanies obesity.

Dr. Sledge on Using Tumor Heterogeneity to Guide Treatment in Breast Cancer

February 28th 2015

George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine, explains how tumor heterogeneity impacts patient care and research.